These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 26631239)
21. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. Gibbs P; Gebski V; Van Buskirk M; Thurston K; Cade DN; Van Hazel GA; BMC Cancer; 2014 Dec; 14():897. PubMed ID: 25487708 [TBL] [Abstract][Full Text] [Related]
22. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Rhee TK; Lewandowski RJ; Liu DM; Mulcahy MF; Takahashi G; Hansen PD; Benson AB; Kennedy AS; Omary RA; Salem R Ann Surg; 2008 Jun; 247(6):1029-35. PubMed ID: 18520231 [TBL] [Abstract][Full Text] [Related]
23. The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres. Pardo F; Sangro B; Lee RC; Manas D; Jeyarajah R; Donckier V; Maleux G; Pinna AD; Bester L; Morris DL; Iannitti D; Chow PK; Stubbs R; Gow PJ; Masi G; Fisher KT; Lau WY; Kouladouros K; Katsanos G; Ercolani G; Rotellar F; Bilbao JI; Schoen M Ann Surg Oncol; 2017 Sep; 24(9):2465-2473. PubMed ID: 28653161 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres. Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137 [TBL] [Abstract][Full Text] [Related]
26. A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates. Mancini R; Carpanese L; Sciuto R; Pizzi G; Golfieri R; Giampalma L; Cappelli A; Galaverni MC; Blotta A; Fiore F; Izzo F; Lastoria S; Mastro A; Di Marzo M; Cagol PP; Gasparini D; Geatti O; Bacchetti S; Pasqual E; Zeuli M; Paoletti G; Garufi C; Cosimelli M; In Vivo; 2006; 20(6A):711-4. PubMed ID: 17203751 [TBL] [Abstract][Full Text] [Related]
27. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. Kim HS; Shaib WL; Zhang C; Nagaraju GP; Wu C; Alese OB; Chen Z; Brutcher E; Renfroe M; El-Rayes BF Cancer; 2018 May; 124(9):1992-2000. PubMed ID: 29451701 [TBL] [Abstract][Full Text] [Related]
28. Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial. Gulec SA; Pennington K; Wheeler J; Barot TC; Suthar RR; Hall M; Schwartzentruber D Am J Clin Oncol; 2013 Oct; 36(5):455-60. PubMed ID: 22643569 [TBL] [Abstract][Full Text] [Related]
29. Y90 selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not? Yilmaz E; Engin MN; Özkan ZG; Kovan B; Büyükkaya F; Poyanli A; Sağlam S; Başaran M; Türkmen C Nucl Med Commun; 2020 Dec; 41(12):1242-1249. PubMed ID: 32941405 [TBL] [Abstract][Full Text] [Related]
30. The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer. Soydal C; Kucuk ON; Gecim EI; Bilgic S; Elhan AH Nucl Med Commun; 2013 May; 34(5):501-6. PubMed ID: 23478586 [TBL] [Abstract][Full Text] [Related]
31. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863 [TBL] [Abstract][Full Text] [Related]
32. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. Sato KT; Lewandowski RJ; Mulcahy MF; Atassi B; Ryu RK; Gates VL; Nemcek AA; Barakat O; Benson A; Mandal R; Talamonti M; Wong CY; Miller FH; Newman SB; Shaw JM; Thurston KG; Omary RA; Salem R Radiology; 2008 May; 247(2):507-15. PubMed ID: 18349311 [TBL] [Abstract][Full Text] [Related]